After systematically testing 1.2 billion drug candidates, Damon Runyon Fellow Fangyu Liu, PhD, and her colleagues may have discovered a safer way to target CaSR, a protein that has been implicated in kidney disease and several cancers. “This ambitious approach exceeded our expectations,” Dr. Liu said. Read more: (fb)

We are delighted to announce our most recent class of Damon Runyon Fellows! These 13 scientists will receive four years of independent funding to investigate cancer causes, mechanisms, therapies, and prevention. In addition, the Foundation has also named five recipients of the Damon Runyon-Dale F. Frey Award for Breakthrough Scientists. This award recognizes Damon Runyon Fellows who have exceeded the Foundation’s highest expectations and are most likely to make paradigm-shifting breakthroughs that transform the way we prevent, diagnose, and treat cancer. “The Fellowship’s emphasis on innovation has inspired me to pursue bold, high-risk ideas that I might have otherwise hesitated to explore,” said 2025 Dale Frey Awardee Fangyu Liu, PhD. Read more: https://bit.ly/4kv5JLF (fb)